135 related articles for article (PubMed ID: 38196127)
1. Cost-effectiveness of catheter-based radiofrequency renal denervation for the treatment of uncontrolled hypertension: an analysis for the UK based on recent clinical evidence.
Sharp ASP; Cao KN; Esler MD; Kandzari DE; Lobo MD; Schmieder RE; Pietzsch JB
Eur Heart J Qual Care Clin Outcomes; 2024 Jan; ():. PubMed ID: 38196127
[TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness of renal denervation therapy for the treatment of resistant hypertension in the UK.
Gladwell D; Henry T; Cook M; Akehurst R
Appl Health Econ Health Policy; 2014 Dec; 12(6):611-22. PubMed ID: 25086585
[TBL] [Abstract][Full Text] [Related]
3. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
[TBL] [Abstract][Full Text] [Related]
4. Cost Effectiveness of Endovascular Ultrasound Renal Denervation in Patients with Resistant Hypertension.
Taylor RS; Bentley A; Metcalfe K; Lobo MD; Kirtane AJ; Azizi M; Clark C; Murphy K; Boer JH; van Keep M; Ta AT; Barman NC; Schwab G; Akehurst R; Schmieder RE
Pharmacoecon Open; 2024 Jan; ():. PubMed ID: 38289517
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness and clinical effectiveness of catheter-based renal denervation for resistant hypertension.
Geisler BP; Egan BM; Cohen JT; Garner AM; Akehurst RL; Esler MD; Pietzsch JB
J Am Coll Cardiol; 2012 Oct; 60(14):1271-7. PubMed ID: 22981547
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness of Renal Denervation Therapy for Treatment-Resistant Hypertension: A Best Case Scenario.
Chowdhury EK; Reid CM; Zomer E; Kelly DJ; Liew D
Am J Hypertens; 2018 Sep; 31(10):1156-1163. PubMed ID: 30010694
[TBL] [Abstract][Full Text] [Related]
7. Potential lifetime cost-effectiveness of catheter-based renal sympathetic denervation in patients with resistant hypertension.
Dorenkamp M; Bonaventura K; Leber AW; Boldt J; Sohns C; Boldt LH; Haverkamp W; Frei U; Roser M
Eur Heart J; 2013 Feb; 34(6):451-61. PubMed ID: 23091202
[TBL] [Abstract][Full Text] [Related]
8. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of Intensive vs Standard Blood Pressure Control Among Older Patients With Hypertension.
Liao CT; Toh HS; Sun L; Yang CT; Hu A; Wei D; Melgarejo J; Zhang ZY
JAMA Netw Open; 2023 Feb; 6(2):e230708. PubMed ID: 36848091
[TBL] [Abstract][Full Text] [Related]
10. Renal Denervation for Treating Hypertension: Current Scientific and Clinical Evidence.
Weber MA; Mahfoud F; Schmieder RE; Kandzari DE; Tsioufis KP; Townsend RR; Kario K; Böhm M; Sharp ASP; Davies JE; Osborn JW; Fink GD; Euler DE; Cohen DL; Schlaich MP; Esler MD
JACC Cardiovasc Interv; 2019 Jun; 12(12):1095-1105. PubMed ID: 31221299
[TBL] [Abstract][Full Text] [Related]
11. A novel, proof-of-concept radiofrequency renal denervation strategy to improve procedural efficiency: 12-month results from the SPYRAL DYSTAL pilot study.
Sharp ASP; Kandzari DE; Townsend RR; Kario K; Mahfoud F; Weber MA; Schmieder RE; Tsioufis K; Böhm M; Choi JW; Liu M; DeBruin V; Lee DP
Cardiovasc Revasc Med; 2024 Apr; ():. PubMed ID: 38616460
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of renal denervation therapy for the treatment of resistant hypertension in The Netherlands.
Henry TL; De Brouwer BF; Van Keep MM; Blankestijn PJ; Bots ML; Koffijberg H
J Med Econ; 2015 Jan; 18(1):76-87. PubMed ID: 25367314
[TBL] [Abstract][Full Text] [Related]
13. Clinical effectiveness and cost-effectiveness of second- and third-generation left ventricular assist devices as either bridge to transplant or alternative to transplant for adults eligible for heart transplantation: systematic review and cost-effectiveness model.
Sutcliffe P; Connock M; Pulikottil-Jacob R; Kandala NB; Suri G; Gurung T; Grove A; Shyangdan D; Briscoe S; Maheswaran H; Clarke A
Health Technol Assess; 2013 Nov; 17(53):1-499, v-vi. PubMed ID: 24280231
[TBL] [Abstract][Full Text] [Related]
14. Renal Denervation in the treatment of Resistant Hypertension.
Yap LB; Balachandran K
Med J Malaysia; 2021 Nov; 76(6):893-897. PubMed ID: 34806679
[TBL] [Abstract][Full Text] [Related]
15. Clinical effectiveness and cost-effectiveness results from the randomised controlled Trial of Oral Mandibular Advancement Devices for Obstructive sleep apnoea-hypopnoea (TOMADO) and long-term economic analysis of oral devices and continuous positive airway pressure.
Sharples L; Glover M; Clutterbuck-James A; Bennett M; Jordan J; Chadwick R; Pittman M; East C; Cameron M; Davies M; Oscroft N; Smith I; Morrell M; Fox-Rushby J; Quinnell T
Health Technol Assess; 2014 Oct; 18(67):1-296. PubMed ID: 25359435
[TBL] [Abstract][Full Text] [Related]
16. Health and Economic Evaluation of Sacubitril-Valsartan for Heart Failure Management.
Bhatt AS; Vaduganathan M; Claggett BL; Fonarow GC; Packer M; Pfeffer MA; Shah SJ; Shen X; Cristino J; McMurray JJV; Solomon SD; Gaziano TA
JAMA Cardiol; 2023 Nov; 8(11):1041-1048. PubMed ID: 37755814
[TBL] [Abstract][Full Text] [Related]
17. Ambulatory heart rate reduction after catheter-based renal denervation in hypertensive patients not receiving anti-hypertensive medications: data from SPYRAL HTN-OFF MED, a randomized, sham-controlled, proof-of-concept trial.
Böhm M; Mahfoud F; Townsend RR; Kandzari DE; Pocock S; Ukena C; Weber MA; Hoshide S; Patel M; Tyson CC; Weil J; Agdirlioglu T; Fahy M; Kario K
Eur Heart J; 2019 Mar; 40(9):743-751. PubMed ID: 30608521
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland.
Soini E; Virtanen O; Väätäinen S; Briere JB; Bowrin K; Millier A
Adv Ther; 2020 Jul; 37(7):3348-3369. PubMed ID: 32519113
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes.
Guzauskas GF; Rind DM; Fazioli K; Chapman RH; Pearson SD; Hansen RN
J Manag Care Spec Pharm; 2021 Apr; 27(4):455-468. PubMed ID: 33769850
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
